Download JUMO’s China Rare Disease Whitepaper

A practical guide for international Rare Disease companies assessing regulatory, commercial, and go-to-market risk in China.

This white paper outlines market dynamics, common failure points, and a structured entry framework designed to support informed, capital-efficient decision-making.

What You Will Receive

This white paper is written for decision-makers assessing China as a strategic market for rare disease therapies, not as a short-term or opportunistic expansion.

It is grounded in first-hand regulatory and market access experience, including orphan drug pathways, NMPA interactions, reimbursement dynamics, and direct engagement with clinicians, KOLs, patient groups, and ecosystem stakeholders across China.

The document is practical, structured, and evidence-driven, designed to support internal strategy, investment, and market-entry decision-making — not promotional content.